Company Overview
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform designed to regulate protein function using FDA-approved small-molecule drugs and is advancing tumor-infiltrating lymphocyte (TIL) cell therapies that leverage mbIL15 to enhance persistence, antitumor activity, and clinical safety. Access to investigational therapies is currently limited to participation in clinical trials, and the company collaborates with other organizations to apply its platform technology. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Why Investors Should Care
Generates a return on equity of 37.8%, reflecting efficient use of shareholder capital.
Carries low leverage with a debt-to-equity ratio of 0.10.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +7.03% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | -31.89% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- RSI (14)41.80 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 37.8%.
CONS
- Trading 46.5% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OBX Obsidian Therapeutics, Inc. PHARMA | 18.73 | -12.08 | $1.16B | 0.00% | -144.32% | 37.82% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2026 |
|---|---|
| Net Income | 0 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 91.25M | 105.67M |
| Operating Income | -91.25M | -105.67M |
| EBITDA | -89.73M | -104.18M |
| Interest Expense | - | - |
| Pretax Income | -83.11M | -100.61M |
| Tax Provision | 0 | 0 |
| Net Income | -83.11M | -100.61M |
| Diluted EPS | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Total Assets | 183.71M | 88.58M |
| Current Assets | 172.85M | 81.52M |
| Cash & Equivalents | 49.76M | 40.41M |
| Inventory | - | - |
| Receivables | - | - |
| Total Liabilities | 358.14M | 354.62M |
| Current Liabilities | 16.09M | 15.36M |
| Long Term Debt | - | - |
| Total Debt | 6.81M | 4.28M |
| Total Equity | -174.43M | -266.04M |
| Shares Outstanding | - | - |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -75.00M | -90.39M |
| Investing Cash Flow | -53.87M | 81.02M |
| Financing Cash Flow | 162.51M | 20.00K |
| Capital Expenditure | -779.00K | -73.00K |
| Free Cash Flow | -75.78M | -90.47M |
| Net Change in Cash | 33.64M | -9.36M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | - | - |
| Net Margin % | - | - |
| ROE % | 47.6% | 37.8% |
| ROCE % | -54.4% | -144.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OBX
Obsidian Therapeutics (OBX) Stock Dropped, So What Is Behind The Attention Now?
Obsidian Therapeutics (OBX) is back in focus after enrolling the first patient in a registration enabling cohort for its Agni-01 trial of amsoki-cel in advanced melanoma, along with fresh index and capital structure moves. Investors are wei…
Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls
Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls
Best Buy downgraded, Bristol Myers upgraded: Wall Street's top analyst calls
Best Buy downgraded, Bristol Myers upgraded: Wall Street's top analyst calls
Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma
CAMBRIDGE, Mass., August 05, 2026--Obsidian Therapeutics, Inc. ("Obsidian") (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) c…
OBX — Frequently Asked Questions
What is the current share price of Obsidian Therapeutics, Inc. (OBX)?
As of 2026-09-19 21:16 PDT, Obsidian Therapeutics, Inc. (OBX) trades at $18.73 on NasdaqCM. Its 52-week range is $15.57 to $35.00.
What is the market capitalisation of OBX?
Obsidian Therapeutics, Inc. (OBX) has a market capitalisation of $1.16B on NasdaqCM.
What is the P/E ratio of OBX?
OBX trades at a trailing price-to-earnings (P/E) ratio of -12.08. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -1.36.
What is the return on equity (ROE) of OBX?
OBX has a return on equity (ROE) of 37.82%. Its return on capital employed (ROCE) is -144.32%.
Is OBX a good stock to buy?
This page provides a data-driven analysis of Obsidian Therapeutics, Inc. (OBX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.